HOME >> BIOLOGY >> NEWS
Preventing graft-versus-host disease disease after bone marrow transplant -- without toxicity

organ failure and death. It strikes some 30-60 percent of transplant patients, depending on how closely matched the donor is, and is kept in check only by eliminating otherwise useful donor immune cells or by using powerful immune-suppressing drugs.

Studies in mice had shown that the chemotherapy regimens used in HSCT not only wipe out white blood cells (with the intended effect of suppressing the immune system), but also damage the intestinal lining. This breach of the lining allows endotoxin, which is produced by bacteria living in the intestines, to enter the bloodstream. The endotoxin, in turn, provokes an inflammatory response that mobilizes donor immune cells, helping to trigger GVHD.

Levy, in Childrens Division of Infectious Diseases, had long been studying BPI, which naturally blocks and neutralizes endotoxin.(1) BPI is found in neutrophils, the very white blood cells that are virtually wiped out by pre-transplant chemotherapy. Studies in mice had shown that blocking endotoxin reduces the incidence of GVHD after chemotherapy and HSCT.(2)

Intrigued by these findings, Levy and Guinan began to study endotoxin and BPI in human patients undergoing HSCT with pre-transplant chemotherapy. In 2003 they showed, in a study of 57 children, that patients blood endotoxin levels rise markedly within a week of the transplant.(3) And now, in a study of 30 patient:donor pairs to be presented at the ASH meeting, they show that patients undergoing HSCT also have a sharp drop in BPI levels just as their endotoxin levels are rising and that BPI deficiency is associated with a greater likelihood of GVHD.

"BPI is markedly deficient 100 to 1000-fold lower in our transplant patients," says Guinan, associate director of the Center for Clinical and Translational Research at Dana-Farber. "If we can replenish this host defense factor, we might be able to moderate the damaging effects of GVHD."

The multicenter clinical trial, expec
'"/>

Contact: Anna Gonski
anna.gonski@childrens.harvard.edu
617-355-6420
Children's Hospital Boston
11-Dec-2006


Page: 1 2 3

Related biology news :

1. Preventing and treating lung cancer -- ESMO explores collaboration to fight cancer on all fronts
2. Preventing cancer without killing cells
3. Preventing obesity in children -- research highlights physical activity levels
4. Preventing ventilation induced lung injury depends on giving the right number of sighs
5. Preventing bacterial biofilms could help fight TB
6. Preventing fetal exposure to popular acne drug
7. Preventing a pandemic: Study suggests strategies for containing a flu outbreak
8. Size matters: Preventing large mammal extinction
9. Preventing muscle atrophy
10. Undesirable expatriates: Preventing the spread of invasive animals
11. Preventing SCD1 expression prevents obesity

Post Your Comments:
(Date:10/28/2014)... Health (NIH) announced awards to expand the Office ... Center for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare ... network, physician scientists at 22 consortia will work ... research and investigate new treatments for patients with ... $29 million in fiscal 2014 funding from NIH. ...
(Date:10/28/2014)... in a novel environment are linked to individual ... experimental study completed at the University of Eastern ... Institute. The study used novel, long-term observations of ... to analyse if behaviours predict the vulnerability to ... enriched hatchery rearing environments. Based on the ...
(Date:10/28/2014)... associated with a lower risk of developing ovarian cancer, ... Anglia (UEA). , Research published today reveals that ... subclasses of dietary flavonoids) significantly decrease their risk of ... death among women. , The research team studied ... and 55 for more than three decades. , ...
Breaking Biology News(10 mins):NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Fish 'personality' linked to vulnerability to angling 2Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
(Date:10/30/2014)... October 30, 2014 2014 Deep ... Industryā€¯ is a professional and in-depth research report ... basic Naltrexone HCL information, including its definition, classification, ... industry overview. This research covers the international market ... global industry analysis covering macroeconomic environment & economic ...
(Date:10/30/2014)... San Diego, CA (PRWEB) October 30, 2014 ... company announced today that they have manually curated public ... Pharma and non profit customers. the data is ... BioSciences manually curates and unifies public and internal data ... more value and knowledge out of the data that ...
(Date:10/30/2014)... New York, NY (PRWEB) October 30, 2014 ... investment plan for its ICH Stability Testing and Package ... companies, this investment centers on a dramatic increase in ... larger volume of stability, storage and aging samples to ... first stage of this major capital expenditure has already ...
(Date:10/30/2014)... , Oct. 30, 2014 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... 8:30 a.m. ET in Boston, MA. ... available on the "Investors & Media" section of the Company,s ... the Isis website within 48 hours and will be archived ...
Breaking Biology Technology:Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Rancho BioSciences Manually Curated TCGA Data Sets Available 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 2Whitehouse Labs Announces Major Capital Investment in Stability and Storage Testing Capacity 3Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2
Cached News: